Lacidip 2 Tablet

Hypertension, Storke prevention

Oral Hypertension Adult: Initially, 2 mg once daily, may increase after 3-4 wk to 4 mg/day. Max: 6 mg/day. Hepatic impairment: Severe: Reduce dose.

May be taken with or without food.

Within 1 mth of MI, cardiogenic shock, unstable angina, aortic stenosis.

Conduction abnormalities, congenital or acquired QT prolongation, poor cardiac reserve. Hepatic impairment. Pregnancy and lactation.

Not Classi

Additive effect w/ diuretics, ACE inhibitors and beta-blockers. May increase plasma level w/ cimetidine. Metabolism may be affected by CYP3A4 inhibitors (e.g. itraconazole) and inducers (e.g. rifampicin). May attenuate antihypertensive effect w/ corticoids or tetracosactid

Headache, flushing, oedema, dizziness, palpitations, aggravation of angina, increased alkaline phosphatase. Rarely asthenia, rash (e.g. erythema and itching), gastric upset, nausea, gum hyperplasia, polyuria, muscle cramps, mood disturbances.

Lacidipine is a potent dihydropyridine Ca antagonist mainly selective for Ca channels in the vascular smooth muscle. It dilates peripheral arterioles resulting in reduced peripheral vascular resistance and BP.

Lacidip 2 2 mg Tablet manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Lacidipine.